Lisa spent 16 years at Schering-Plough and Merck across Global Regulatory Affairs, Clinical Research, and Global Medical Affairs, where she led a team of 15 regional medical directors. Since 2006 her focus has been liver disease; she is a member of AASLD and has co-authored more than 35 publications in NEJM, Lancet, and Hepatology. She holds a doctorate in neuropharmacology from the University of Pennsylvania.

Steve has over 30 years of experience in pharmaceutical and biotech new-product planning, business intelligence, finance, product launch, and global marketing. He led new-product and lifecycle planning teams at Schering-Plough and Daiichi-Sankyo, and continues to assess licensing opportunities across gastroenterology and hepatology. Steve is a CPA and earned his MBA in Finance from Seton Hall University in New Jersey.

Paul has 30 years in the pharmaceutical industry at Vinchem, Inc., where he acts as the sales agent for foreign manufacturers of APIs and finished dosage forms from Europe, India, and China. He has developed and licensed products for Paragraph IV and 505(b)(2) filings and was a founding member of a virtual pharmaceutical development and marketing start-up. He holds a BS from the University of Notre Dame and an MBA from Seton Hall University.

Catherine has over 25 years across pharma and biotech, focused on early-stage development and commercial strategy. She served as VP of Commercial Development at Arbutus Bio and VP of Medical Affairs at Antios Therapeutics. During 17 years at Abbott and AbbVie she helped advance HCV products including VIEKIRA and MAVYRET from preclinical through FDA approval and U.S. launch. Earlier roles include Roche, Bristol-Myers Squibb, and Merck.